Stellus Capital Investment (NYSE:SCM – Get Free Report) and Advanced Medical Isotope (OTCMKTS:RDGL – Get Free Report) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.
Insider and Institutional Ownership
13.2% of Stellus Capital Investment shares are owned by institutional investors. 4.0% of Stellus Capital Investment shares are owned by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Stellus Capital Investment and Advanced Medical Isotope, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stellus Capital Investment | 0 | 3 | 0 | 0 | 2.00 |
| Advanced Medical Isotope | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Stellus Capital Investment and Advanced Medical Isotope’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stellus Capital Investment | 29.77% | 10.72% | 3.95% |
| Advanced Medical Isotope | -6,144.90% | N/A | -113.56% |
Volatility and Risk
Stellus Capital Investment has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.5, suggesting that its share price is 150% less volatile than the S&P 500.
Earnings & Valuation
This table compares Stellus Capital Investment and Advanced Medical Isotope”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stellus Capital Investment | $104.74 million | 3.72 | $45.85 million | $1.09 | 12.35 |
| Advanced Medical Isotope | $30,000.00 | 1,038.52 | -$2.91 million | N/A | N/A |
Stellus Capital Investment has higher revenue and earnings than Advanced Medical Isotope.
Summary
Stellus Capital Investment beats Advanced Medical Isotope on 9 of the 11 factors compared between the two stocks.
About Stellus Capital Investment
Stellus Capital Investment Corporation is a business development company specializing in investments in private middle-market companies. It invests through first lien, second lien, unitranche, and mezzanine debt financing, often with a corresponding equity investment. The fund prefers to invest in US and Canada. The fund seeks to invest in companies with an EBITDA between $5 million and $50 million.
About Advanced Medical Isotope
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
Receive News & Ratings for Stellus Capital Investment Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellus Capital Investment and related companies with MarketBeat.com's FREE daily email newsletter.
